This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Generess Fe

Allergan plc

Drug Names(s): 0.8 mg norethindrone + 0.025 mg ethinyl estradiol with 75 mg ferrous fumarate tablets; WC3026

Description: Generess Fe combines 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets.

Deal Structure: Warner Chilcott and Watson
In January 2009, Warner Chilcott granted Watson an exclusive license to market and sell an oral contraceptive product (WC3026) currently in late-stage development. Warner Chilcott is responsible for completing development and obtaining approval of this product. Warner Chilcott will exclusively supply Watson with the product on a cost plus margin basis and Watson will pay Warner Chilcott royalties based on product net sales.

In January 2013, Watson changed its name to Actavis.

Warner Chilcott and Actavis
In May 2013, Actavis and Warner Chilcott announced they have entered into a definitive agreement under which Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. The proposed transaction has been unanimously approved by the Boards of Directors of Actavis and Warner Chilcott and is supported by the management teams of both companies.

In October 2013, Actavis...See full deal structure in Biomedtracker


Generess Fe News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug